SCHEMBL469277

SCHEMBL469277

COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)c(F)c3)ccnc2cc1OCC1(NCC2CC2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 12/20 0.67
AXL P30530 12/20 0.67
KDR P35968 4/20 0.67
FLT1 P17948 3/20 0.67
AURKB Q96GD4 3/20 0.67
MERTK Q12866 3/20 0.67
AURKA O14965 1/20 0.67
RIPK2 O43353 1/20 0.67
ABCB11 O95342 1/20 0.67
ABL1 P00519 1/20 0.67
EGFR P00533 1/20 0.67
ERBB2 P04626 1/20 0.67
NTRK1 P04629 1/20 0.67
LCK P06239 1/20 0.67
PGR P06401 1/20 0.67
LYN P07948 1/20 0.67
RET P07949 1/20 0.67
CHRM2 P08172 1/20 0.67
HCK P08631 1/20 0.67
ADRA2A P08913 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL469263 0.95 AURKB (0.58) METAXLKDRFLT1AURKB
SCHEMBL469356 0.94 AURKB (0.60) METAXLKDRFLT1AURKB
SCHEMBL469309 0.90 MET (0.66) METAXLKDRFLT1AURKB
SCHEMBL469304 0.89 MET (0.65) METAXLKDRFLT1AURKB
SCHEMBL469352 0.89 MET (0.77) METAXLKDRFLT1AURKB
SCHEMBL469290 0.88 MET (0.63) METAXLKDRFLT1AURKB
SCHEMBL469289 0.88 MET (0.63) METAXLKDRFLT1AURKB
SCHEMBL469305 0.88 AXL (0.62) METAXLKDRFLT1AURKB
SCHEMBL469307 0.88 AXL (0.62) METAXLKDRFLT1AURKB
SCHEMBL469298 0.87 MET (0.62) METAXLKDRFLT1AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621904-B1 COMPOUNDS AS C-MET KINASE INHIBITORS ADVENCHEN LABORATORIES LLC (US) 2020-04-22 EP disclosed
US-8664244-B2 Compounds as c-Met kinase inhibitors Advenchen Pharmaceuticals, LLC (US) 2014-03-04 US disclosed
US-20120123126-A1 Compounds As c-Met Kinase Inhibitors CHEN GUOQING PAUL (US) 2012-05-17 US disclosed
WO-2012034055-A2 COMPOUNDS AS C-MET KINASE INHIBITORS ADVENCHEN LABORATORIES, LLC (US) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120123126-A1 Compounds As c-Met Kinase Inhibitors MET, MERTK, HGF MET 1/4885AXL 75/4885KDR 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.